• Vaccine Name: N. caninum DNA vaccine encoding NcSAG1 and NcSRS2, combined with recombinant NcSAG1 and NcSRS2 Proteins
• Target Pathogen: Neospora caninum
• Target Disease: Neosporosis
• Vaccine Ontology ID: VO_0004163
• Type: DNA vaccine
• Status: Research
• SAG1 gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• SRS2 gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0000132
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Host Strain: C57BL/6
• Vaccination Protocol: The infected positive control group was treated as before. To the mice of the adjuvant control group, 100μl of the pcDNA3 vector without insert (used at a concentration of 1 mg/ml) was inoculated intramuscularly, with 50 μl (corresponding to 50 μg of DNA) being injected into the right and left hind limb muscle, respectively, on day 0 and on day 28. On day 49, these adjuvant control mice received one single i.p. injection of PBS–RAS as in the previous experiments. Group 3 received similar intramuscular applications of pcDNA3–NcSAG1 at day 0 and day 28, followed by a single i.p. injection of 200 [mu]l of recNcSAG1 (75 μg/ml) emulsified in PBS at day 49. Group 4 received treatment with pcDNA3–NcSRS2 and recNcSRS2 as in group 3 (Cannas et al., 2003).
• Challenge Protocol: On day 59, all mice were challenged i.p. with 2×10^6 live N. caninum tachyzoites suspended in 200 μl of PBS (Cannas et al., 2003).
• Efficacy: Results suggest that a combined DNA/recombinant antigen-vaccine, based on NcSAG1 and NcSRS2, respectively, exhibited a highly significant protective effect against experimentally induced cerebral neosporosis in mice (Cannas et al., 2003).